Reversible Linkers for Protein Therapeutic Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering protein therapeutics, such as antibodies and cytokines, face challenges due to intrinsic instability, immunogenicity, and short half-life, limiting their effectiveness and safety in cancer treatment, particularly in maintaining high numbers of viable tumor-specific cytotoxic T lymphocytes.
Innovation Solution
Development of biodegradable linkers that allow for the reversible conjugation and cross-linking of protein monomers into clusters, known as 'backpacks,' which can be used to deliver therapeutic proteins directly to cells, enhancing their stability and bioactivity while minimizing systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If protein therapeutics are delivered using engineered carriers (encapsulation/adsorption or conjugation), then delivery efficiency can be improved, but bioactivity is reduced or manufacturing efficiency is low
Solution Approach 1:
The patent changes the chemical parameters of the linker system by using reversible covalent bonds with specific kinetics (fast association, slow dissociation) to maintain protein bioactivity while achieving efficient delivery. The linker design parameters (length, flexibility, hydrolysis rate) are optimized to balance stability during delivery with reversibility for bioactivity maintenance.
Solution Approach 2:
The patent introduces a reversible linker as an intermediary between the protein therapeutic and the delivery system. This intermediary allows controlled association and dissociation, enabling efficient delivery while preserving bioactivity through reversible binding rather than permanent conjugation.
2Productivity
If protein therapeutics are conjugated to deliver them, then delivery efficiency is improved, but conjugation reduces bioactivity
Solution Approach 1:
The patent applies dynamic covalent chemistry where the linker forms reversible bonds that can associate and dissociate under physiological conditions. This dynamic system allows the protein to maintain bioactivity by reversible binding rather than static conjugation, while still achieving efficient delivery through controlled association.
Solution Approach 2:
The patent optimizes the kinetic parameters of the reversible linker (association rate constant k_on, dissociation rate constant k_off) to achieve fast binding for efficient delivery but slow dissociation to maintain stable complex formation, while preserving protein bioactivity through reversible rather than irreversible conjugation.
3Productivity
If encapsulation or adsorption is used to load proteins, then delivery can be achieved, but efficiency is typically inefficient
Solution Approach 1:
The patent replaces physical encapsulation/adsorption mechanisms with chemical reversible covalent bonding. This substitution of mechanism enables efficient loading through specific chemical reactions rather than inefficient physical entrapment, while maintaining delivery effectiveness through controlled reversible dissociation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these linkers enables efficient and safe delivery of biologically active agents to cells, improving the therapeutic efficacy of protein therapeutics by maintaining high viability and function of transferred T lymphocytes, thereby enhancing anti-tumor activity with reduced side effects.
Implementation Method 1
The cross-linking of the protein monomers can be effected by a number of mechanisms including, for example, hydrolysis of a disulfide bond in the linker
Implementation Method 2
LG1 and LG2 are each a leaving group, independently selected from triflate, tosyl, Cl, N-hydroxysuccinimide and imidazolide
Data Source
AI summary
Disclosed herein are compositions and methods for preparation and delivery of protein therapeutics, and more particularly reversible linkers and use thereof.